Revolution Medicines cut the risk of death by 60% with daraxonrasib. How far can the RAS platform expand?
Revolution Medicines’ RASONQUE has become the first broad RAS-targeted therapy approved for metastatic pancreatic adenocarcinoma after Phase 3 data showed a 60% reduction in the risk of death compared with chemotherapy. The approval matters well beyond one cancer because it tests whether RAS, long regarded as one of oncology’s hardest targets, can support an entire
